Clinical Evaluation of Lyral® Dose Response Study

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Contact Dermatitis
Interventions
BIOLOGICAL

Lyral®

Alergen panel containing ascending doses of Lyral (0.10 mg/cm\^2, 0.20 mg/cm\^2 and 0.40 mg/cm\^2) and negative control

Trial Locations (1)

DK-5000

University of Southern Denmark Institute of Clinical Research, Odense

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allerderm

INDUSTRY

NCT02028182 - Clinical Evaluation of Lyral® Dose Response Study | Biotech Hunter | Biotech Hunter